SCHEMBL6084151

SCHEMBL6084151

O=C(Nc1cccc(-c2n[nH]cc2-c2nc3ccccc3o2)c1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.61
KDM4E B2RXH2 6/20 0.60
SMN1; SMN2 Q16637 5/20 0.60
POLB P06746 5/20 0.60
DUSP1 P28562 4/20 0.60
ALDH1A1 P00352 4/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
GAA P10253 2/20 0.54
HSD17B10 Q99714 2/20 0.54
HPGD P15428 1/20 0.54
THRB P10828 1/20 0.52
TP53 P04637 1/20 0.52
USP2 O75604 1/20 0.52
NPSR1 Q6W5P4 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
LMNA P02545 1/20 0.51
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6084168 0.90 MAPT (0.70) MAPTKDM4ESMN1; SMN2POLBDUSP1
SCHEMBL6085606 0.90 MEN1 (0.55) MAPTKDM4ESMN1; SMN2POLBDUSP1
SCHEMBL6086053 0.90 AGPAT2 (0.64) MAPTKDM4ESMN1; SMN2POLBDUSP1
SCHEMBL6085394 0.90 MAPT (0.58) MAPTKDM4ESMN1; SMN2POLBDUSP1
SCHEMBL6086017 0.89 ALDH1A1 (0.58) MAPTKDM4ESMN1; SMN2POLBALDH1A1
SCHEMBL6086548 0.86 MAPT (0.49) MAPTKDM4ESMN1; SMN2POLBDUSP1
SCHEMBL6084969 0.86 LMNA (0.64) MAPTKDM4ESMN1; SMN2POLBDUSP1
SCHEMBL6086892 0.85 USP2 (0.74) MAPTKDM4EPOLBALDH1A1MEN1
SCHEMBL6085757 0.84 NAMPT (0.55) MAPTKDM4EPOLBALDH1A1MEN1
SCHEMBL6085135 0.84 MAPT (0.52) MAPTKDM4ESMN1; SMN2POLBDUSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP disclosed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 MAPT 801/4885KDM4E 1175/4885SMN1; SMN2 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.